Neovascularization: The Main Mechanism of MSCs in Ischemic Heart Disease Therapy

Weili Shi1,2, Qiqi Xin1,2, Rong Yuan1,2, Yahui Yuan1,2, Weihong Cong1,2* and Keji Chen1,2

1 Laboratory of Cardiovascular Diseases, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China,
2 National Clinical Research Center for Chinese Medicine Cardiology, Beijing, China

Mesenchymal stem cell (MSC) transplantation after myocardial infarction (MI) has been shown to effectively limit the infarct area in numerous clinical and preclinical studies. However, the primary mechanism associated with this activity in MSC transplantation therapy remains unclear. Blood supply is fundamental for the survival of myocardial tissue, and the formation of an efficient vascular network is a prerequisite for blood flow. The paracrine function of MSCs, which is throughout the neovascularization process, including MSC mobilization, migration, homing, adhesion and retention, regulates angiogenesis and vasculogenesis through existing endothelial cells (ECs) and endothelial progenitor cells (EPCs). Additionally, MSCs have the ability to differentiate into multiple cell lineages and can be mobilized and migrate to ischemic tissue to differentiate into ECs, pericytes and smooth muscle cells in some degree, which are necessary components of blood vessels. These characteristics of MSCs support the view that these cells improve ischemic myocardium through angiogenesis and vasculogenesis. In this review, the results of recent clinical and preclinical studies are discussed to illustrate the processes and mechanisms of neovascularization in ischemic heart disease.

Keywords: mesenchymal stem cells, ischemic heart disease, neovascularization, angiogenesis, vasculogenesis

INTRODUCTION

Ischemic heart disease (IHD) is characterized by reduced blood supply to the heart and is the leading cause of death and disability worldwide. Long-term myocardial ischemia and acute massive myocardial infarction often result in decreased left ventricular function. Although the development of new drugs and the use of stent implantations have benefited numerous patients with coronary heart disease, some patients still have no effective treatment due to issues associated with diffuse coronary artery lesion, postoperative restenosis and heart failure after myocardial infarction (MI).

The foundation of IHD treatment is the reconstruction of vessels and the recovery of blood flow. Over the past decades, with the introduction of the concept of therapeutic angiogenesis, more and more studies have demonstrated that neovascularization can effectively improve the blood supply of ischemic myocardium. There are two primary mechanisms by which neovascularization occurs: vasculogenesis and angiogenesis. Vasculogenesis is the in situ assembly of endothelial progenitors into capillaries, while angiogenesis is a process through which new blood vessels form from pre-existing vessels through sprouting and intussusception (1). Cytokine-based therapeutic angiogenesis from the bench to clinical trials has been a major focus of medical research, and the efficacy of vascular endothelial growth factor (VEGF) blockers has led to the approval of
anti-angiogenesis drugs for cancer and eye disease. Conversely, the use of angiogenesis factors, such as VEGF and basic fibroblast growth factor (bFGF), has been shown to promote notable increases in collateral vessel and myocardial perfusion in ischemic myocardium, reduced infarct size and improved cardiac function (2), demonstrating the theoretical and experimental promise of this approach in treating ischemic diseases. Unfortunately, despite the exciting results obtained using angiogenesis factors to treat IHD, gene therapy is also limited by its restricted efficacy and resistance (3). For example, VEGF also accelerates angiogenesis in atherosclerotic plaques and promotes plaque growth, which may eventually lead to plaque instability, while it promotes angiogenesis in ischemic tissue, an observation referred to as the famous Janus phenomenon (4). Angiogenesis greatly improves blood flow in myocardial ischemia, but the safety of growth factor-based angiogenesis therapy is an issue that remains to be overcome. Thus, how to avoid the risks associated with angiogenesis therapy is a problem that must be considered.

Stem cell-based therapies provide a promising new method for the formation of new blood vessels. MSCs have become the most promising seed cells for the treatment of IHD, with advantages of rapid self-renewal, multidifferentiation potential, and weak immunogenicity in autologous transplantation. Clinical and preclinical studies have shown that MSC therapy effectively limits the infarcted area and improves heart function. However, the mechanisms associated with the activities of MSCs in IHD therapy remain controversial. We primarily attribute the cardiac protective effect of MSCs to their ability to promote neovascularization for the following two reasons. First, MSCs secrete soluble paracrine factors that contribute to angiogenesis and vasculogenesis. Second, MSCs are able to differentiate into ECs, pericytes and smooth muscle cells (SMCs), which form the foundation of vessels, processes that both participate in the protective ability of MSCs toward IHD. In this review, we focus on the mechanisms and clinical applications of MSCs in IHD therapy through neovascularization to provide reference for the application of stem cells in IHD.

### COMPARISON OF MSCS FROM DIFFERENT SOURCES

MSCs can be isolated from bone marrow, adipose tissue, umbilical cord blood, peripheral blood and almost every tissues in adults. Although MSCs can be harvested from different sources, regardless of their origin, they all have the capability of differentiating into adipocytes, osteoblasts and chondroblasts in vitro under specific conditions and can adhere to plastic under culture conditions. Furthermore, the surface of MSCs displays CD73, CD90, and CD105 but lack CD34, CD45, HLA-DR, CD14 or CD11b, CD79a or CD19. The International Society for Cell Therapy proposed the three criteria described above as identification standards for MSCs (5). Although MSCs from different sources share many of the same biological features, there are also some differences between distinct MSC populations. Bone marrow-derived MSCs (BMSCs), adipose-derived MSCs (AMSCs) and umbilical cord-derived MSCs (UCMSCs) are the most popular MSCs in clinical and preclinical experiments and trials, and some of their capabilities are compared below (Table 1).

### Differentiation Capacity

MSCs have the ability to differentiate into adipocytes, osteoblasts and chondroblasts. The amount of calcium deposits and sulfated proteoglycans stained by Alizarin red and Alcian blue, respectively were both higher in BMSCs than that observed in AMSCs, indicating that BMSCs have a higher capacity toward osteogenic and chondrogenic differentiation than AMSCs. While similar adipogenic differentiation potential was observed between these two types of cells (6), some studies have reported that AMSCs are more prone to adipogenic differentiation than BMSCs (7). Baksh et al. (8) observed that compared to BMSCs, UCMSCs underwent osteogenic differentiation more rapidly, exhibited higher alkaline phosphatase activity, and generated significantly more fat-containing cells when grown under adipogenic conditions by day 21. The differentiation ability of stem cells is affected by donor sex, age, isolation and culture conditions, etc. (9). Thus, which types of MSCs have a greater ability to differentiate into adipocytes, osteoblasts and chondroblasts remains disputed. In addition, MSCs also have the ability to differentiate into ECs, pericytes and SMCs, which are necessary components of blood vessels (10–13). Lu et al. (14) showed that MSCs from adipose tissue may have significantly greater ability to promote angiogenesis both in vitro and in vivo than UCMSCs and endometrial MSCs.

### Proliferation Capacity

MSCs from different tissue sources do not have the same proliferative ability in vitro. Choudhery et al. (15) observed that UCMSCs have higher population doublings than AMSCs (33.0 ± 1.5 vs. 25.8 ± 0.6), with the doubling time being longer for AMSCs (2.7 ± 0.03 days) than UCMSCs (2.0 ± 0.04 days). Moreover, after prolonged passaging (30 times), the proliferative ability of UCMSCs did not change significantly, while BMSCs showed decreased proliferation after 6 passages (8), indicating that UCMSCs have a stronger proliferative ability than BMMSCS and AMSCs. Under human platelet lyase-supplemented culture conditions, AMSCs were observed to have greater proliferative

### TABLE 1 | Comparison of MSCs from different sources.

| Differentiation capacity          | BMSCs | AMSCs | UCMSCs |
|----------------------------------|-------|-------|--------|
| Osteogenesis                     | ++    | +     | +++    |
| Chondrogenesis                   | ++    | +     | +++    |
| Adipogenesis                     | +     | +     | +++    |
| Endothelial cells                | +     | +     | +      |
| Pericytes                        | +     | +     | +      |
| Smooth muscle cells              | +     | +     | +      |
| Proliferation capacity           | +     | +     | +++    |
| Migration capacity               | + +   | +     | ++     |
| Tube formation                   | +     | +     | +      |
potential than BMSCs (6). Therefore, the proliferative ability of UCMSCs is the strongest, followed by AMSCs and BMSCs.

Migration Capacity
MSCs play an important role in posttraumatic tissue repair and cell therapy, and their migration ability is a key factor affecting their therapeutic efficacy. The migration capacity of BMSCs and placenta-derived MSCs (PMSCs) was observed to be 5.9- and 3.2-fold higher than that of UCMSCs, respectively. These results were consistent with the observed levels of migration-enhancing proteins in UCMSCs, including cathepsin B, cathepsin D and prohibitin, which were significantly lower than those observed in BMSCs and PMSCs, while the levels of migration-inhibiting proteins such as plasminogen activator inhibitor-1 and manganese superoxide dismutase were higher (16). Vimentin also contributed to the higher migration capability of BMSCs than UCMSCs (17). In contrast, UCMSCs exhibited an enhanced migration capacity toward factors released by hepatocellular carcinoma compared with BMSCs (18).

Capacity of MSCs to Promote Tube Formation of ECs
Tube formation is the last step in the formation of vessels and is necessary to supply blood for ischemia. Pill et al. (19) showed that AMSCs and BMSCs are both promising cell types to induce vascularization with ECs in vitro and are promising candidates to support in vivo vascularization. Nevertheless, Kim et al. (20) observed that conditioned medium from human AMSCs showed better tube formation-promoting effects than that from BMSCs in vitro, and AMSC group showed better recovery of blood flow than BMSC group in hindlimb ischemia model of nude mice. Furthermore, young AMSCs may have a higher tube formation capacity than old ones (21). UCMSCs are also capable of forming tubular networks (22). Du et al. (23) reported tube numbers of 11.65 ± 2.92, 0.91 ± 0.76 and 0.41 ± 0.20 for BMSC, AMSC and UMSC groups, respectively, indicating that BMSCs may have better angio-vasculogenic capacities than UMSCs and AMSCs. In contrast, Panepucci et al. (24) thought that UCMSCs would be more committed to angiogenesis and BMMSCs would be more committed to osteogenesis. Above all, there is still no consensus on which cell type has the greater capacity to promote tube formation.

PARACRINE FUNCTION OF MSCS THROUGHOUT THE NEOVASCULARIZATION PROCESS

The mechanism of MSC therapy is still controversial, because few MSCs can be found in myocardium after injection in vivo study. Wang et al. (25) showed that most intravenously injected MSCs remain in the lungs and liver, with only a small portion reaching the myocardial tissue. Similarly, Uemura et al. (26) observed only a few GFP-labeled MSCs in the perinfarct myocardium. Even so, clinical and preclinical studies still indicated the cardiac function of ischemic heart was improved, and infarct size and the number of apoptotic cardiomyocytes were significantly reduced after MSCs intervention. Which suggested the efficacy of MSCs did not benefited from themselves in some degree.

Paracrine hypothesis was firstly advanced by Gneccchi et al. (27). They found genetically modified BMSCs overexpressing the Akt1 released paracrine factors that exert cytoprotective effects on cardiomyocytes exposed to hypoxia and limited infarct size and improved ventricular function (27, 28). Furthermore, high VEGF, bFGF, IGF-1 and SDF-1 expression in hypoxia-preconditioned MSCs medium was examined, the results of which indicated that the paracrine function of MSCs may play more important role than their differentiation ability (26). Recently, it has been reported that MSCs secreted a wide array of cytokines that exerted beneficial angiogenesis in ischemic tissue, including PDGF, thrombopoietin, and angiogenin (29, 30). These factors are all involved in the neovascularization process, including MSC mobilization, migration, homing, adhesion and retention, and the differentiation of ECs. Especially VEGF and bFGF, which both have high affinity toward heparin and participate in angiogenic processes such as migration and amplification of ECs, are also necessary substances to induce the transformation of stem cells into ECs (10, 31). MSCs overexpressing Akt and angioptetin-1 showed higher Flk1 and Flt1 positivity and promoted intrinsic Flk1+ and Flt1+ cell mobilization into the infarcted heart (32). Huang et al. (33) observed that overexpression of miR-126 promoted the differentiation of MSCs toward ECs through activation of the PI3K/Akt and MAPK/ERK pathways and the release of VEGF and bFGF factors. Therefore, paracrine factors secreted by MSCs may have pivotal functions throughout the neovascularization process. The role of various secretory factors in the neovascularization process will be discussed below.

IN VolvEMENT OF MSCs IN THE NEOVASCULARIZATION PROCESS

The process by which MSCs promote neovascularization involves in a number of steps. First, once ischemia occurs which also follows stress change, MSCs can perceive the associated changes and are mobilized from their niches to migrate and adhere to ischemic tissue to proliferate and differentiate. Notably, MSCs secrete various factors, including chemokines and growth factors, and this paracrine function is carried out throughout the neovascularization process (Figure 1). The completion of all biological processes depends on the cooperation of different types of cells, and the neovascularization process requires the collaboration of ECs, endothelial progenitor cells (EPCs) and pericytes. In addition, exosomes derived from MSCs act as a messenger that participate in cell-to-cell communication.

Environmental Perception by MSCs
Perception of Hypoxia by MSCs
Despite the benefits of MSC transplantation in cardiac tissue, detailed in vivo observations have shown that MSCs only survive for a brief period after engraftment due to harsh microenvironmental conditions (including ischemia, inflammation and anoikis) in the infarcted myocardium (34).
FIGURE 1 | The complete process by which MSCs respond to ischemia. In general, MSCs are stored in their niches, which retain adult stem cell in a dormant state. Once tissue is damaged, signals, including those involve in ischemia-associated pathways, cell-cell interaction and stress mobilize stem cells to migrate from the stem-cell niche to damaged tissues, where they adhere, self-renew and differentiate. Once ischemia occurs, MSCs have the ability to secrete a number of growth factors through their paracrine function to promote new tube formation of ECs to provide new blood for ischemic tissue.

However, this environment contributes to the mobilization of MSCs from their niches.

MSCs originated from the bone marrow microenvironmental niche exhibit low oxygen tension. O$_2$ is a necessary factor in the maintenance of cell life as the final receptor in the intracellular aerobic respiration electron transport chain and is a substrate of some enzymes. Once the supply of O$_2$ is insufficient, the hypoxia signal will be rapidly transmitted to nucleus and initiate related gene expression to maintain oxygen homeostasis and the balance of energy metabolism between the cells and organism. Hypoxia inducible factor 1 (HIF-1), which has a dimeric complex composed of HIF-1a and HIF-b subunits, is oxygen-sensitive and the most important transcription factor affecting gene regulation under hypoxia (35). Once ischemia occurs, HIF-1 increases the expression of angiogenesis-associated genes, including VEGF, its receptors Flk-1 and Flt-1, bFGF and the fibrinogen system (36, 37). At the same time, HIF-1 improves the expression of proteases, such as membrane type matrix metalloproteinases, which hydrolyzes extracellular protein to promote cell migration, matrix reconstruction and the formation of tube-like structures (38).

Hypoxia is also a basic aspect of the microenvironment that determines the differentiation of MSCs. Compared with a normoxia group, VEGF expression in embryonic and MSCs under hypoxia was observed to be significantly increased (39–41). Likewise, the in vivo administration of hypoxia-inducible VEGF-engineered MSCs was shown to induce ischemia-responsive VEGF production and lead to a significant increase in myocardial neovascularization after myocardial infarction in rats (39).

**Cell-Cell Interactions**

In 1997, Asahara et al. (42) identified and named a small population of CD34$^+$ cells as “EC progenitors.” Indeed, EPCs are involved in a number of processes during angiogenesis, including mobilization, differentiation into ECs, homing, paracrine function and others (43, 44). Coculture of EPCs and MSCs significantly increased the transcription levels of endothelial specific markers, including vWF, CD31, VE-cadherin, Flk-1 and Flt-1 (45) and enhanced tube-like formation (46) through platelet derived growth factor (PDGF), Notch and TACE/TNF alpha signaling (45, 47). Joensuu et al. (48) noted that in cocultures of human MSCs and peripheral blood mononuclear cells, the previously nonadherent cells attached and started to elongate and form tube-like structures within 1 week concomitant with VEGFR1 upregulation, and platelet endothelial cell adhesion molecule 1 (PECAM-1) and endoglin-positive vessel-like structures were observed after 20 days. In addition, MSC-EC interactions were observed to decrease endothelial permeability induced by lipopolysaccharide through hepatocyte growth factor (HGF) by restoring the integrity of endothelial monolayers and remodeling endothelial intercellular junctions (49). VEGF secreted by stem cells from apical papilla is also used by human umbilical vein endothelial cells to increase the number of endothelial tubules, tubule lengths, and branching points (50).
Laminar Shear Stress and Pulsatile Stress

There are many force-sensitive molecules on the cell surface, such as cilia, integrins, ion channels and plaque proteins. Integrins connect the cytoskeleton and extracellular matrix through adhesive plaque and transform the force signals into intracellular biological signals through this plaque (51, 52). Considering the key role of shear force in the differentiation of ECs, researchers reported that such mechanical stimulation in cell culture in vitro was equally effective for the differentiation of stem cells into ECs (53). MSCs are highly reactive to mechanical stimuli in the environment, and different types of stress on the same MSC population will lead to different differentiation results (54). After generating canine BMSCs under shear stress provided by a pulsatile bioreactor for 4 days, the expression of endothelial cell markers, such asPECAM-1, VE-cadherin and CD34 was observed to be significantly increased (55). Fisher et al. (56) noted that AMSCs could form cords but failed to take up acetylated low density lipoprotein (acLDL) or express molecular markers after being cultured in endothelial cell growth supplement. Only the subsequent exposure of stem cells to shear stress did the cells exhibit realignment, acLDL uptake and CD31 expression, indicating that stem cells differentiation to ECs requires the synergism of biochemical and shear force.

Dynamic Process of MSCs to Repair Ischemic Tissue

**Mobilization**

MSC mobilization is key for its involvement in tissue repair following their sensing of hypoxia, stress or other signals. An anoxic environment is one of the factors that induces stem cells to migrate out of their niches. Prolyl hydroxylase (PHD) and factor inhibiting HIF-1 (FIH) are key oxygen sensors in MSCs. HIF-1α upregulation by double knockdown of PHD and FIH synergistically increases stem cell mobilization and myocardial angiogenesis and improves cardiac function (57). The high concentration of growth factors outside of stem-cell niches may be another factor causing MSCs to mobilize from their original niches. Stromal cell-derived factor-1 (SDF-1 α)/CXCR4 and insulalike growth factor-1 (IGF-1) are key oxygen sensors in MSCs. HIF-1α upregulation by double knockdown of PHD and FIH synergistically increases stem cell mobilization and myocardial angiogenesis and improves cardiac function (57).

**Migration and Homing of MSCs**

Homing and migration comprise a key step after MSC mobilization. Microenvironmental interactions between hypoxia and MSCs may control the ability of MSCs to migrate and their migration direction. In hypoxic tissue, SDF-1 and CXCR-4 are also important factors for cell migration. Ischemic myocardial and vascular tissues secrete SDF-1 to attract CXCR-4-expressing cells, particularly their therapeutic progenitors. Yu et al. (62) showed that SDF-1/CXCR-4 may mediate the migration of BMSCs toward heart MI through activation of PI3K/Akt signaling. Growth factors play an important role in the process of MSC migration. The stimulation of SDF-1α expression in infarcted hearts by VEGF-overexpressing MSCs was observed to result in the massive mobilization and homing of BMSCs (59). TGF-β1, HGF, IGF-1 and endothelial nitric oxide synthase (eNOS) also promoted the migration and homing BMSCs to the ischemic myocardium (63-65). Schmidt et al. (31) showed that low concentrations of bFGF attracted cells, indicating that bFGF may direct the migration of MSCs. In addition, Yan et al. (66) observed that C1q/tumor necrosis factor-related protein-9 (CTRP9) enhances AMSC proliferation and migration through the ERK1/2-MMP-9 signaling pathway and also promotes anti-apoptotic/cell survival via ERK-Nrf2/anti-oxidative protein expression. MiRNA, like miR-206 also involved in migration of MSCs by targeting Pim-1 (67).

Proliferation and Survival

Although MSCs transplantation is a promising therapeutic approach for IHD, the low viability of MSCs after transplantation needs to be improved. Hypoxic preconditioning may improve the functional survival and therapeutic efficiencies of engrafted BMSCs, at least in part through autophagy regulation (68). Some growth factors, including increased VEGF, TGF-β, IGF-1, SDF-1α and angiogenin were shown to enhance MSC survival and vasculogenesis in an MI model (69). Preconditioning with other factors, such as protein kinase C epsilon (εPKC), CTRP9, dimethylxalylglycine and connexin-43 improves the retention and survival of transplanted MSCs in rat MI through the SDF-1/CXC and PI3K/AKT pathways (66). Qu et al. (70) showed that atorvastatin, a hypolipidemic agent, has a protective effect on cardiomyocytes against apoptotic cell death in infarct and peri-infarct areas and could also increase the survival rate of implanted BMSCs in acute myocardial ischemia.

Adhesion and Retention

MSCs need to stay and adhere to ischemic tissue to play their important role in ischemic tissue repair. Molecular imaging studies have shown that <5% of MSCs engraft in ischemic tissues after being intravenously injected, with most of them dying within few hours after administration (74). This poor engraftment may be attributed to the constant blood flow and the harsh environmental conditions after acute ischemic injury. Since the long-term efficacy of cell therapy is proportional to the number of retained cells, this low retention and viability needs to be improved. Increasing the ability of MSCs to adhere to the ischemic tissues is key to improving their retention and viability. IGF-1 can increase the adhesion of MSCs and prolong their survival under hypoxia in vitro through PI3K activation (75). MSC adhesion can also be promoted by increasing the expression of integrin-linked kinase, periostin, and 2, 4-dinitrophenol (76–78). Reactive oxygen species (ROS) inhibit the cellular adhesion of engrafted MSCs, indicating that the elimination of ROS may be a novel strategy for improving the survival of engrafted MSCs.
The stimulated angiogenic activity of ECs is associated with the secretion of various growth factors and cytokines, including VEGF, HGF, IL-6, TGF-

In addition to the interactions between MSCs and ECs, studies showed MSCs had the ability to differentiate into ECs to promote angiogenesis in some degree although it was still controversial. For example, Otto et al. (86) did not observe MSC transdifferentiation into cardiomyocytes, ECs or SMCs and that the transdifferentiation of MSCs into cardiomyocytes or vascular cells did not significantly contribute to the improvement of cardiac function. Conversely, Silva et al. (87) showed that BMSCs promoted the angiogenesis of dog ischemic myocardium by differentiating into ECs, which accelerated the establishment of collateral circulation. Studies support MSCs own the potential to differentiated into ECs according to the below reasons. First, MSCs are multipotent stem cells derived from the mesoderm. Theoretically, MSCs can be differentiated into all mesoderm derived cells, and since ECs are mesoderm-derived cells, MSCs have the potential to differentiate into ECs. Second, MSCs express molecular markers of early ECs, such as VEGF receptor 2 (VEGFR-2/Flik-1/KDR) and bFGF, indicating that ECs can be derived from mesenchymal colonies and that MSCs arise from precursors with angiogenic potential (31, 88). Last, a series of in vivo and in vitro experiments proved that MSCs can differentiate into ECs. Oswald et al. (10) successfully used 2% fetal bovine serum supplemented with 50 ng/mL VEGF to induce BMSCs to differentiate into ECs in vitro. They observed that differentiated cells increased the expression of endothelial-specific markers, such as KDR and VEGF receptor 1 (VEGFR-1/Flt-1), and formed capillary-like structures. Furthermore, the process of MSC differentiation into ECs may require the synergy of bFGF, IGF, epidermal growth factor (EGF) (89, 90). ERK signaling may also involve in the differentiation of porcine AMSCs into ECs (90).

Furthermore, MSCs also function with EPCs to promote tissue repair. As a precursor of ECs, EPCs also differentiate into ECs and promote ischemia angiogenesis through their paracrine function (91, 92). MSCs could attract and promote the migration and vascularization of EPCs, which may depend on a positive feedback loop between CXCR-2 and CXCR-4 (93, 94). The viability and ability of MSCs to promote nerve regeneration is also improved by EPCs through PDGF-BB/PDGFR-β signaling (95). Rossi et al. (96) found MSCs and EPCs into the hind limbs of ischemic model together accelerated ischemic muscle recovery through an endoglin-dependent mechanism. Consequently, MSCs, ECs and EPCs may have a synergistic effect in ischemic tissue repair (Figure 2).

Pericytes, also known as mural cells, wrap around ECs in arterioles, capillaries and venules to regulate the maturation of ECs, stabilize the microvascular wall and promote angiogenesis. Although pericytes are surrounded by a basement membrane, they contact the ECs with through a “peg and socket” mechanism through holes in the basement membrane. Studies have shown that pericytes also communicate with ECs via paracrine signaling to improve tissue repair (97, 98). It is notable that pericytes also have stem cell-like properties and exhibit the morphology, mitotic activity and surface antigens of MSCs (99) and are


differentiation into new ECs and the repair of injured ECs. Last, MSCs also interact with EPCs to influence EC formation and function.

**INTERACTIONS AMONG MSCS AND ECs, EPCS AND PERICYTES**

Multiple cell types are known to be involved in the processes of angiogenesis and vasculogenesis, including MSCs, ECs, EPCs and pericytes. In particular, ECs are indispensable for angiogenesis and the relationship between MSCs and ECs mainly attribute to the following aspects. First, MSCs secret growth factors which can repair the injured but not dead ECs through their paracrine function. Second, the interaction and crosstalk between MSCs and existing ECs promotes the formation of new ECs and the repair of injured ECs. Third, MSCs have the potential to differentiate into new ECs although it is controversial. Last, MSCs also interact with EPCs and pericytes to influence EC formation and function (Figure 2).

The ability of MSCs to limit infarct size may attributed to their pro-angiogenesis activity through existing ECs (Figure 2). The stimulated angiogenic activity of ECs is associated with the secretion of various growth factors and cytokines, including VEGF, HGF, IL-6, TGF-β1 and monocyte chemoattractant protein-1 (81). Lu et al. (82) showed that nestin(+) BMSC transplantation improved cardiac function in a mouse AMI model by recruiting resident cardiac ECs to the infarcted border region. BMSCs also rescued injured ECs through modulation of mitophagy or activation of signaling pathways such as PI-3K/AKT/m-TOR/eNOS and p38/MAPK (83, 84). Hypoxia also influences the interactions between the endothelium and MSCs (85).

**FIGURE 2** MSCs and endothelial cells. The relationship between MSCs and ECs can be summarized as follows. First, MSCs can repair the injured but not dead ECs through their paracrine function to induce the release of growth factors. Second, MSCs have the potential to differentiate into new ECs although it is controversial. Third, the interaction and crosstalk between MSCs and existing ECs promotes the formation of new ECs and the repair of injured ECs. Last, MSCs also interact with EPCs to influence EC formation and function.
seemingly able to differentiate into adipocytes, chondrocytes, osteoblasts, neurons, astrocytes and oligodendrocytes, leading them to be identified as MSCs (100–102). However, it is still debated whether pericytes are MSCs. Guimaraes-Camboa et al. (103) challenged this concept and suggested that mural cells do not intrinsically behave as MSCs during aging and repair in multiple adult organs using a transgenic cell line. Over 2 years, the study showed that Tbx18 lineage-derived cells maintained their perivascular identity in the brain, heart, muscle and fat, indicating that mural cells do not exhibit an overt potential to give rise to other cell types. In contrast, MSCs can serve as a potential source of pericytes and induce vasculogenesis as indicated that mural cells do not exhibit an overt potential to give rise to other cell types. Furthermore, MSCs secrete various growth factors, including PDGF, which serves as a biomarker and crucial factor controlling the differentiation and recruitment of pericytes (106–108). These findings indicate that MSCs may regulate the recruitment of pericytes to injured tissue to participate in angiogenesis, but the associated mechanisms between MSCs and pericytes need to be further elucidated.

**MSCS AND MSC-DERIVED EXOSOMES**

Exosomes are a type of extracellular microvesicle secreted by multiple eukaryotes. Compared with cell therapy, MSC-derived exosomes (MSC-exos) have lower immunogenicity and are safer and more efficient, providing a new strategy for tissue regeneration via cell-free therapy (109, 110). MSC-exos are a type of message carrier that harbor a modifiable content of microRNAs, mRNAs and proteins, mediating communication between cells and functioning as key mediators of the paracrine effect of MSCs (111, 112). The pro-angiogenesis function of MSC-exos has been demonstrated in a number of studies. For instance, exosomes from MSCs overexpressing Akt, HIF-1α or CXCR-4 were shown to accelerate EC proliferation, migration and tube-like structure formation in vitro, as well as blood vessel formation to improve cardiac function in an MI model (113–115). MSC-exosomes may also have anti-inflammatory activities in MI model (116). Currently, the application of MSC-exos primarily focuses on preclinical experiments. One of the key problems for exosome clinical therapy is how to collect and purify enough exosomes so that they can be used safely. Andriolo et al. (117) developed a GMP-class method for the mass preparation of stem cell-derived exosomes to enable them to be used in future clinical applications. Indeed, as they are secreted by MSCs, MSC-exos have similar biological properties to MSCs to some extent. MSC-exos also have paracrine functions and mediate communication between MSCs and ECs, and they are also influenced by microenvironmental stress conditions, such as hypoxia and irradiation (118, 119). Furthermore, as they harbor a part of and not the entirety of MSC contents, MSC-exos are not an MSC “mini-me” and cannot replace MSCs in some respects, including their multiple differentiation and proliferation abilities.

**APPLICATION OF MSCS IN IHD CLINICAL AND PRECLINICAL PRACTICE**

The results of numerous clinical and preclinical studies have indicated that MSC transplantation is safe, significantly improves cardiac function and decreases infarct size and fibrosis in ischemic patients, which may be associated with the survival, retention, angiogenesis, paracrine action and the anti-apoptosis activities of MSCs (Tables 2, 3). Although cellular therapies hold great promise for the treatment of human IHD and have good safety, the efficacy of MSCs remains disputable, especially when used in clinical trials. Meta-analyses of randomized clinical trials showed that the transplantation of BMSCs resulted in limited improvement on cardiac function for MI patients (171, 172). As it was showed in Table 2, some clinical trials proved MSC transplantation did not improve LVEF although it may limit infarct size. Different from clinical trials, MSC transplantation in animal experiments showed significantly elevated LVEF in most studies (Table 3).

Clinical patients are different from animal ischemia models, and the efficacy of MSCs in clinical practice is influenced by many different factors, such as (1) disease etiology and severity of patients, and (2) the type, number, delivery route and time, retention, survival, proliferation and differentiation of MSCs. Another meta-analysis showed that MSCs are more effective in patients with lower baseline left ventricular ejection fraction (LVEF) (<50%), and the effects of cells that were transferred at 3–7 days post-AMI was superior to those transferred within 24 h or more than 7 days in improving LVEF and decreasing LV end-systolic and diastolic dimensions (173), which suggested transplantation time was a key factor to influence cardiac function. Compared with clinical trials, animal experiments are easier to obtain positive results because of their simplicity, such as the MI model can be established uniformly by ligation of the left anterior descending coronary artery. Compared with MSCs intervention alone, pretreated MSCs with some growth factors together may get more efficacy (Table 3).

It is notable except for growth factors, more attention has been paid to natural botanical medicines. EGb761, an extract of *Ginkgo biloba*, was shown to exhibit a biphasic effect on hypoxia/serum deprivation-induced BMSC apoptosis, and its effect was closely associated with the PI3K/Akt and caspase-9 signaling pathways (174). *Salvia miltiorrhiza* is a widely used traditional Chinese medicine in cardiovascular diseases, and its constituent Tan shinone IIA was observed to decrease infarct size by increasing the recruitment of BMSCs to the infarct region by upregulating the SDF-1/CXCR-4 axis in a rat MI model (175). In addition to botanical medicines, chemicals such as statins, as the most commonly used lipid-lowering agents, exert activity toward a wide spectrum of cellular functions in addition to their lipid-lowering effects, including anti-inflammatory, anti-apoptotic, anti-fibrotic and pro-angiogenesis effects (176, 177). The results of multiple studies have suggested that atorvastatin has the ability to increase the survival rate of implanted BMSCs in an MI model, and combined with MSCs, it also ameliorated the cardiac milieu by reducing inflammatory cell infiltration, myeloperoxidase
| NCT          | Conditions | Interventions                  | Phase | Patients No/ follow-up | Endpoint                                                                 | LVEF improved | Study type   | Cell quantity | Method | Data               | References |
|--------------|------------|--------------------------------|-------|------------------------|---------------------------------------------------------------------------|---------------|--------------|---------------|--------|--------------------|------------|
| NCT00950274 | MI         | CD133^+ ABMSCs                 | III   | 82/6 mon               | LVEF, LVEDV, LVESV, scar size, LV mass, NT-proBNP                          | Yes           | R,PA,D       | 0.5–5x10^6    | IM     | 2009.7–2016.3      | (123)      |
| NCT00669227 | AMI        | ABMCs                          | II    | 42/6 mon               | LVEF, LVEDV, LVESV, infarct size                                         | No            | R,PA,D       | 381 x 10^6    | ICA    | 2005.10–2009.1     | (121)      |
| NCT00893360 | MI/LVD     | Autologous cardiosphere-derived stem cells | I     | 25/6 mon              | Safety, LVEF, scar mass, systolic wall thickening                         | No            | R,PA,N       | 12.5–25 x 10^6 | ICA    | 2009.5–2012.2      | (123)      |
| NCT01033617 | MI/AMI     | ABMCs/CD133^+                  | –     | 42/6 mon               | LVEF, LVEDV, LVESV                                                        | No            | R,PA,Q       | 0.5–10 x 10^6   | IM     | 2009.10–2016.6     | (125)      |
| NCT00279175 | AMI        | ABMCs                          | II    | 204/12 mon             | LVEF                                                                       | Yes           | R,PA,D       | 236 x 10^6     | ICA    | 2004.4–2010.10     | (126, 127) |
| NCT0114452  | MI         | Autologous hMSCs               | I     | 53/6 mon               | Safety, LVEF, LV remodeling                                              | Yes           | R,PA,D       | 0.5, 1.6, 5 x 10^6/kg | ICA    | 2005.2–2009.2      | (128)      |
| NCT01291329 | STEMI      | Human umbilical WJ-MSC         | II    | 116/18 mon             | Safety, LVEF, perfusion                                                  | Yes           | R,PA,Q       | 6 x 10^6       | ICA    | 2011.2–2012.7      | (129)      |
| NCT00883727 | AMI        | Allogeneic BMSCs               | I/II  | 20/2 year              | Safety, LVEF, perfusion, infarct volume                                  | No            | R,PA,D       | 2 x 10^5/kg     | ICA    | 2009.4–2012.8      | (130)      |
| NCT00765453 | MI         | ABMCs                          | II    | 100/12 mon             | LVEF, infarct size, NT-proBNP                                            | No            | R,PA,T       | 59.8 (1.9CD34^+) x 10^6 | ICA    | 2008.3–2018.3      | (131)      |
| NCT00264316 | STEMI      | ABMCs                          | II    | 67/4 mon               | LVEF, LVEDV, LVESV, infarct size, systolic wall thickening               | No            | R,SA,D       | 304 (72MNCs) x 10^6 | ICA    | 2003.5–2005.12     | (132)      |
| NCT00199823 | AMI        | ABMMCs                         | II    | 100/12 mon             | Prothrombotic markers, LV function                                       | No            | R,PA,S       | 68 x 10^6      | ICA    | 2003.9–2006.5      | (133, 134) |
| NCT00313339 | STEMI      | ABMSC CD34+                    | I     | 31/6 mon               | Safety, LVEDV, LVESV, LVEF, infarct size, perfusion                      | No            | R,FA,N       | 5, 10, 15 x 10^6 CD34^+ cells | ICA    | 2006.3–2013.3      | (135)      |
| NCT00684060 | IHD/LVD    | ABMSC                          | II    | 80/6 mon               | LVEF, wall motion, LV volumes, infarct size, relationship of Ratio of CD133^+,CD34^+ cells on LVEF | Yes           | R,PA,D       | 150 x 10^6      | ICA    | 2008.7–2012.2      | (136–139) |
| NCT00684021 | STEMI/IHD/LVD | ABMSC                       | II   | 120/6 mon              | Safety, LVEF, wall motion, LV function                                   | No            | R,PA,D       | 150 x 10^6      | ICA    | 2008.7–2012.11     | (139)      |
| NCT00355186 | STEMI      | ABM-MNCs                       | II    | 95/12 mon              | LVEF, LV volumes, infarct size                                          | No            | R,FA,N       | 153 (119) x 10^6 | ICA    | 2008.6–2012.11     | (140)      |
| NCT01167751 | MI         | BM-MNCs; CD133^+ cells         | II/III| 90/6,18 mon            | Safety, LVEF, systolic wall thickening                                   | Yes           | R,PA,D       | MNCs:584.63 x 10^6; CD133^+ cells:8.19 x 10^6 | IM     | 2008.1–2012.7      | (141)      |

(Continued)
| NCT | Conditions | Interventions | Phase | Patients No/ follow-up | Endpoint | LVEF improved | Study type | Cell quantity | Method | Data | References |
|-----|------------|---------------|-------|------------------------|---------|--------------|------------|--------------|--------|------|------------|
| NCT00268307 | AMI | ABMCs | I | 40/6 mon | LVEF, LVEDV | Yes | R, CA, D | 100 × 10⁶ | ICA | 2005.12–2010.9 | (144) |
| NCT02439398 | AMI | Allogeneic hCSCs | I/II | 49/12 mon | Safety, infarct size | – | R,PA,D | 35 × 10⁶ | ICA | 2014.6–2016.11 | (145) |
| NCT00956511 | CABG | ABMMNC | I/II | 60/6 mon | safety, LVEF, LVEDV, LVESV. | Yes | R,PA,D | 100 × 10⁶ | ICA | 2007.1–2009.6 | (146) |
| NCT00418418 | Ischemic HF | ABMMC | II | 39/12 mon | LVEF, LVEDV, LVESV, infarct size, safety. | No | R,FA,Q | 5–1,000 × 10⁶ | ICA | 2006.10–2010.12 | (147, 148) |
| NCT00363324 | STEMI | BMSCs | II/III | 80/6 mon | LVEF, LVEDV, LVESV | Yes | R,PA,D | 360(2.6 CD34+) × 10⁶ | ICA | 2008.1-2009.11 | (149, 150) |
| NCT01495364 | STEMI | CD34+ | II | 161/12 mon | Safety, LVEF, infarct size, | No | R,PA,D | 10 × 10⁶±20% | ICA | 2011.12-2016.4 | (151) |
| NCT00289822 | IHD | BMSCs/CPCs | II | 75/3 mon | LVEF | Yes | R,CA,N | BMSCs: 205 × 10⁶; CPCs:22 × 10⁶ | ICA | 2002.1–2005.1 | (152) |
| NCT01234181 | MI | Hypoxia BMSCs | – | 34/1 year | Safety, LVEF, LVEDV, LVESV, wall motion, perfusion | No | R,PA,N | 10 × 10⁶ | ICA | 2010.11–2012.12 | (153) |
| NCT01076920 | CM/LVD | ABMSCs | I/II | 10/2 year | Safety, LVEF, myocardial viability and contraction | Yes | SA,N | 61.5 × 10⁶ | IM | 2009.10–2014.9 | (154) |
| NCT01087996 | ICM | BMSCs | I/II | 30/13 mon | Safety, LVEF, LVEDV, LVESV, immunologic monitoring, quality of life, pulmonary function | – | R,PA,N | 20, 100, 200 × 10⁶ | TE | 2010.4–2011.9 | (155) |

R, Randomized; PA, Parallel Assignment; FA, Factorial Assignment; CA, Crossover Assignment; SA, Single Group Assignment; DR, Double Randomized Controlled Trial; Q, Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor); T, Triple (Participant, Care Provider, Investigator); D, Double blind; S, Single (Outcomes Assessor); N, None (Open Label); ABMMCs, Autologous Bone Marrow Mononuclear Cells; ABMCs, autologous bone-marrow cells; hCSCs, human cardiac stem cells; LVEDV, Left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; MO, microvascular obstruction; IHD, ischemic heart disease; LVD, left ventricular dysfunction; ICM, ischemic cardiomyopathy.
TABLE 3 | Representative animal studies performed using MSCs in ischemic models.

| Disease model | Animal source | cell source/type | Dose | Method/No. of sites | Treatment/end time | Preclinical outcome | Mechanisms | Specific treatment | References |
|---------------|---------------|------------------|------|---------------------|-------------------|--------------------|-------------|-------------------|------------|
| MI/IR Mice    | mice/ADSCs    | $2 \times 10^6$  | IM/3 | 0 h/-               | ↑LVEF, ↓fibrosis  | ↑ADSCs survival/retention, migration, angiogenesis; ↑cardiomyocyte adhesion, proliferation; ↑MMP-10/13 and/or HGF | N-cadherin | (156)             |
| IR Adult male SD rats | SD rat within 6–7 d/ ADSCs | $2 \times 10^6$  | IV/- | 0, 24 h/24 h, 72 h, 28 d | ↑LVEF, ↓infarct size | ↓Neutrophil number by enhanced M2 macrophage and macrophage efferocytosis | – | (157)             |
| IR Female Gottingen mini-swine | Male Gottingen mini-swine/Cortical bone stem cells | $2 \times 10^7$  | IM/- | 1.5–2 h/3 d, 7 d, 3 mon | ↑LVEF, ↓infarct size | ↑Macrophage and T-cell populations; ↑cardiomyocyte apoptosis | – | (158, 159)       |
| MI Male C57 mice | Human umbilical cord blood-MSCs | $2 \times 10^6$  | IM/4 | 0/- | Protects cardiac function (↓infarct size) | ↑Proliferation/ migration by ERK1/2-MMP-9, ↓apoptotic /oxidant via ERK-Nrf2 | CTRP9 | (66)             |
| MI Male C57/BL6 mice | hMSCs | $2 \times 10^5$  | IM/5 | 30 min/1, 28 d | ↑LVEF, ↓LVEDV, LVESV, scar size, ↑Autophagic flux through exosome containing mainly miR-125b-5p | ↑Pro-angiogenic factors: VEGF, SDF-1a, GM-CSF; Anti-apoptotic, inflammatory and collagen deposition | Exo-MSCs | (161)            |
| MI Female Gottingen swine | Male Yorkshire swine MSCs/CSCs | $200 \times 10^6$/1 x $10^6$  | TE/10 | -/3 mon | ↑LVEF, perfusion, ↓LVEDV, LVEF, scar size, remodeling | ↑Cardiac regeneration | – | (162)            |
| MI C57/BL6 mice; CTRP9 knock-out mice | EGFP-TG mice with C57BL/6J background/ADSCs | $1 \times 10^6$  | IM/3 | 1, 3, 7, 14 d/3 d, 4 w | ↑LVEF, fibrotic area | ↑Proliferation/ migration by ERK1/2-MMP-9, ↓apoptotic /oxidant via ERK-Nrf2 | Exo-SDF1 | (163)            |
| MI C57/BL6 Mice | male C57/BL6/BM-MSCs, ATMSCs | $2 \times 10^5$  | IM/1 | -/IM after 1, 7, 14, and 21 d, LV after 21, 60 d | ↑LVEF, LVFS | ↑BM-MSC adhesion, ↓apoptosis, ↑focal adhesion kinase | CTF1 | (80)             |
| I/R Female Large White pigs | male Large White pigs/ATMSCs | $10 \times 10^5$ | ICA/- | 15 min after reperfusion/2 days, 60 d | ↑Myocardial perfusion (vascular density), not LV Function | Pro-angiogenic factors: VEGF, SDF-1a, GM-CSF; Anti-apoptotic, inflammatory and collagen deposition | – | (163)            |
| MI SD rats | Aged and young male hMSCs | $10 \times 10^6$ | IM/5 | 30 min/28 d | ↑LVEF, ↓fibrosis/scar size | ↑Angiogenesis/ survival; against apoptosis | SRT1720 | (164)            |
| MI C57BL/6 mice | Synthaetic hBMSCS | $1 \times 10^5$  | IM/- | 0/15 d | Mitigated LV remodeling | ↑Angiogenesis | – | (165)            |
| MI Male SD Rats | SD rats/BMSCs | $22 \times 10^6$ | Tail vein | 2 d/IF: weeks 1, 2; 4; LV; 3 d, 1,3,6 w | ↑Cardiac function (LVEF, LVDD, LVSD) | ↑Angiogenesis by the tropism of MSCs to the MI area through SDF-1 | VEGF-encapsulated | (166)            |
| AMI Female Large White pigs | Pigs/ATMSCs | $50 \times 10^6$ | IM/7-8 | 0/2, 15, 30 d | Cardiac function not significantly improved (LVEF) | ↑Inflammation, ↑angiogenic process | IGF-1/HGF | (167)            |

(Continued)
| Disease model | Animal source | cell source/type | Dose | Method/ No. of sites | Treatment/end time | Preclinical outcome | Mechanisms | Specific treatment | References |
|---------------|---------------|------------------|------|----------------------|-------------------|-------------------|------------|------------------|------------|
| MI            | Male Corriedale sheep | Corriedale male sheep/BMSCs | $20 \times 10^6$ | IM/5 | 30 min/30, 60 d | ↓Infarct volume; ↑LVEF | ↓Angio-/arterogenesis, ↓apoptosis by HIF1-mediated overexpression of EPO, INOS, VEGF, and ANG-1 | HIF1-α | (168) |
| CMI           | Female pigs | Human umbilical cord-derived MSCs | $30 \times 10^6$ | ICA/ICV/- | 4, 5, 6 w/ 4 w | ↓LVEF, perfusion; ↓apoptosis, fibrosis | ↑Angiogenesis by VEGF and Ang | – | (169) |
| MI            | Male Cynomolgus monkeys | Cynomolgus monkey/BMSCs | $10 \times 10^6$ | IM/S | 0/3, 28, 90, 180, 270 d | ↑LV function, ↓infarct size | ↑Cardiomyocyte proliferation, vascular density, myocardial glucose uptake, engraftment, paracrine activity (EPO, HIF1-α, ANG-1); ↓endogenous cell apoptosis | Hypoxia | (173) |
| AMI           | SD rat | Male SD rat/BMMSCs | $1 \times 10^6$ | IM/S | 0/1 day, 4 w | ↑LVEF, ↓LVEDD, LVESD, remodeling improved | ↑Retention; SDF-1/CXC and PKCε, ↑survival; VEGF, bFGF, TGFβ, cTnI, VWF, SMA and factor VIII | PKCr | (70) |

ICA, intra-coronary artery infusion; ICV, intra-coronary vein infusion; IM, intramyocardial; TE, transendocardial; ↑, indicators increased or improved; ↓, indicators decreased or worsened.
activity and cardiac fibrosis (178, 179). Furthermore, activation of the JAK-STAT pathway may play important role in the ability of rosuvastatin to increase the efficacy of transplanted MSCs (178). Other factors, including glucagon-like peptide-1-eluting (GLP-1), lipopolysaccharide and lysophosphatidic acid also exert pro-angiogenesis effect by promoting the enhanced expression of cytokines and growth factors (180–183).

STRATEGIES AND FUTURE DIRECTIONS

MSCs display robust reparative properties through their paracrine and differentiation abilities that can limit apoptosis, enhance neovascularization and direct positive tissue remodeling. However, some problems with MSCs remain and must be solved before they can have widespread use. MSCs are important infiltrating cells that are also driven by blood and vasoconstriction. So the first problem is the low survival and retention of transplanted cells in vivo which limits their overall effectiveness in clinical usage. Consequently, identifying strategies to improve cell survival and retention in vivo is a priority. However, cell transplantation is affected by many factors, each of which may have an impact on the survival of transplanted cells, and there is still no consistent recommendation for each factor. The microenvironment of transplanted cells directly affects the survival of stem cells. The blood supply in the marginal area of myocardial infarction is well known to directly affect the survival rate and recovery of cardiac function after cell transplantation. One important goal of cell transplantation is to promote angiogenesis in the ischemic area and reduce the generation of myocardial scars. Studies have shown that hypoxia-induced stem cells release a variety of factors to improve the microenvironment through anti-inflammatory and anti-fibrosis effects and by promoting angiogenesis (170).

Hypoxia or other growth factors used to precondition stem cells may allow MSC survival and retention to be improved, but additional comparisons and a set of standards are needed to identify the most powerful factors.

Another important factor limiting the clinical application of stem cells is the shortage of effective monitoring methods for stem cells. The successful implementation of cell therapies requires a better understanding of cell fate after transplantation. Currently, there are three primary labeling methods for stem cells, including reporter genes, fluorescent dyes and nanoparticles, which require optical imaging, MRI and radiouclide imaging to trace the transplanted stem cells, respectively or in combination, with each technique having its advantages and disadvantages (74, 184). Thus, there is an urgent need to develop a nontoxic and noninvasive tracer technology that exhibits long term stability and that can also be used to dynamically monitor the survival status of transplanted cells with respect to processes such as migration and differentiation in vivo.

AUTHOR CONTRIBUTIONS

WS contributed to the design and manuscript writing. QX, RY, and YY collected and assembled data. WC contributed the review design and financial support. KC was responsible for proofreading and final approval of the review. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by the National Natural Science Foundation of China (No. 81803771).

REFERENCES

1. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. (2011) 473:298–307. doi: 10.1038/nature10144
2. Zachary I, Morgan RD. Therapeutic angiogenesis for cardiovascular disease: biological context, challenges, prospects. Heart. (2010) 97:181–9. doi: 10.1136/hrt.2009.180414
3. Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, et al. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation. (2003) 107:1359–65. doi: 10.1161/01.CIR.0000061911.47710.8A
4. Epstein SE. Janus phenomenon: the interrelated tradeoffs inherent in therapies designed to enhance collateral formation and those designed to inhibit atherogenesis. Circulation. (2004) 109:826–31. doi: 10.1161/01.CIR.0000132468.82942.F5
5. Dominici M, Le Blanc K, Mueller J, Slaper-Cortenbach I, Marini FC, Krause DS, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. (2006) 8:315–7. doi: 10.1080/14653240600855905
6. Li C, Wu X, Tong J, Yang X, Zhao J, Zheng Q, et al. Comparative analysis of human mesenchymal stem cells from bone marrow and adipose tissue under xeno-free conditions for cell therapy. Stem Cell Res Ther. (2015) 6:55. doi: 10.1186/s13287-015-0066-5
7. Pachón-Peña G, Yu G, Tucker A, Wu X, Vendrell J, Bunnell BA, et al. Stromal stem cells from adipose tissue and bone marrow of age-matched female donors display distinct immunophenotypic profiles. J Cell Physiol. (2011) 226:843–51. doi: 10.1002/jcp.22408
8. Baksh D, Yao R, Tuan RS. Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. Stem Cells. (2007) 25:1384–92. doi: 10.1634/stemcells.2006-0709
9. Zhu M, Kohan E, Bradley J, Hedrick M, Benhaim P, Zuk P. The effect of age on osteogenic, adipogenic and proliferative potential of female adipose-derived stem cells. J Tissue Eng Regen M. (2009) 3:290–301. doi: 10.1002/term.165
10. Oswald J, Boxberger S, Jorgensen S, Feldmann S, Ehninger G, Bornhauser M, et al. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells. (2004) 22:377–84. doi: 10.1634/stemcells.22-3-377
11. Gu W, Hong X, Le Bras A, Nowak WN, Issa BS, Deng J, et al. Smooth muscle cells differentiated from mesenchymal stem cells are regulated by microRNAs and suitable for vascular tissue grafts. J Biol Chem. (2018) 293:8089–102. doi: 10.1074/jbc.RA118.017339
12. Jeon ES, Park WS, Lee MJ, Kim YM, Han J, Kim JH, et al. Rho kinase/myocardin-related transcription factor-A-dependent mechanism underlies the sphingosylphosphorylcholine-induced differentiation of mesenchymal stem cells into contractile smooth muscle cells. Circ Res. (2008) 103:635–42. doi: 10.1161/CIRCRESAHA.108.180885
13. Wang HH, Cui YL, Zaorsky NG, Lan J, Deng L, Zeng XL, et al. Mesenchymal stem cells generate pericytes to promote tumor recurrence via vasculogenesis.
after stereotactic body radiation therapy. *Cancer Lett.* (2016) 375:349–59. doi: 10.1016/j.canlet.2016.02.033

14. Lu H, Wang F, Mei H, Wang S, Cheng L. Human adipose mesenchymal stem cells show more efficient angiogenesis promotion on endothelial colony-forming cells than umbilical cord and endometrium. *Stem Cells Int.* (2018) 2018:7537589. doi: 10.1159/2018/7537589

15. Choudhery MS, Badowski M, Muise A, Harris DT. Comparison of human adipose mesenchymal stem cells derived from bone marrow, umbilical cord, and placenta: Implication in the migration. *Proteomics.* (2009) 9:29–30. doi: 10.1002/pmic.200701195

16. Li G, Zhang X, Wang H, Meng C, Chan C, et al. Comparative proteomic analysis of mesenchymal stem cells derived from human bone marrow, umbilical cord, and placenta: Implication in the migration. *Cytobiotherapy.* (2013) 15:330–43. doi: 10.1016/j.jctyl.2012.11.010

17. Huang L, Niu C, Willard B, Zhao W, Liu L, He W, et al. Proteomic analysis of porcine mesenchymal stem cells derived from bone marrow and umbilical cord: implication of the proteins involved in the higher migration capability of bone marrow mesenchymal stem cells. *Stem Cell Res Ther.* (2015) 6:77. doi: 10.1186/s13287-015-0066-x

18. Bayo J, Fiore A, Aquino JB, Malvicini M, Rizzo M, Peixoto E, et al. Human umbilical cord perivascular cells exhibited enhanced migration capacity towards hepatocellular carcinoma in comparison with bone marrow mesenchymal stromal cells: a role for autocrine motility factor receptor. *Biomed Res Int.* (2014) 2014:1–9. doi: 10.1155/2014/837420

19. Pill K, Hofmann S, Redl H, Holthöner W. Vascularization-mediated benefit by mesenchymal stem cells from bone marrow and umbilical cord: a comparison. *Cell Regener.* (2015) 4:8–9. doi: 10.1186/s13169-015-0025-4

20. Kim Y, Kim H, Cho H, Bae Y, Suh K, Jung J. Direct comparison of human mesenchymal stem cells derived from adipose tissue and bone marrow in mediating neovascularization in response to vascular ischaemia. *Cell Physiol Biochem.* (2007) 20:867–76. doi: 10.1159/000101447

21. Efimenko A, Starostina E, Kalinina N, Stolzing A. Angiogenic properties of aged adipose derived mesenchymal stem cells after hypoxic conditioning. *J Transl Med.* (2011) 9:10. doi: 10.1186/1479-5868-9-10

22. Arutyunyan I, Fatkhudinov T, Kananykhina E, Usman N, Elchaninov A, Efimenko A, Starostina E, Kalinina N, Stolzing A. Angiogenic properties of porcine mesenchymal stem cells derived from bone marrow and umbilical cord: a comparison. *Cell Regener.* (2015) 4:8–9. doi: 10.1186/s13169-015-0025-4

23. Del Vecchio ME, Guedes LG, Prado-Lopez S, Conesa A, Martínez-Losa M, Escobedo-Lucea G, Canda G, et al. Hypoxia promotes efficient differentiation of human embryonic stem cells to functional endothelium. *Stem Cells.* (2012) 30:789–809. doi: 10.1002/stem.136

24. Prado-Lopez S, Conesa A, Armià N A, Martínez-Losa M, Escobedo-Lucea G, Canda G, et al. Hypoxia promotes efficient differentiation of human embryonic stem cells to functional endothelium. *Stem Cells.* (2012) 30:789–809. doi: 10.1002/stem.295

25. Koong AC, Denko NC, Hudson KM, Schindler C, Swiercz L, Koch C, et al. Candidate genes for the hypoxic tumor phenotype. *Cancer Res.* (2000) 60:883–7. Available online at: https://cancerres.aacrjournals.org/content/60/4/883.long

26. Wijmenga C, De Jong J, Schalkwijk G, Middeldorp J, van der Velden D, Schouten H, et al. Endothelial progenitor cells: mobilization, isolation of putative progenitor endothelial cells for angiogenesis. *Science.* (1997) 275:964–7. doi: 10.1126/science.275.5302.964

27. Hristov M, Erl W, Weber PC. Endothelial progenitor cells: mobilization, isolation of putative progenitor endothelial cells for angiogenesis. *Science.* (1997) 275:964–7. doi: 10.1126/science.275.5302.964

28. Hristov M, Erl W, Weber PC. Endothelial progenitor cells: mobilization, isolation of putative progenitor endothelial cells for angiogenesis. *Science.* (1997) 275:964–7. doi: 10.1126/science.275.5302.964
60. Wan M, Li C, Zhen G, Jiao K, He W, Jia X, et al. Injury-activated SDF-1alpha/CXCR4 signaling to promote myocardial vasculogenesis in myocardial infarction. Stem Cell Res Ther. (2017) 8:89. doi: 10.1186/s13287-017-0543-0

61. Liu XH, Bai CG, Xu ZY, Huang SD, Yuan Y, Gong DJ, et al. Therapeutic potential of anginogen modified mesenchymal stem cells: anginogen improves mesenchymal stem cells survival under hypoxia and enhances vasculogenesis in myocardial infarction. Microvasc Res. (2008) 76:23–30. doi: 10.1016/j.mvr.2008.02.005

62. Yu H, Zhao ZH, Han FS, Liu XH, Wang R, Zeng YL. Overexpression of protein kinase C varepsilon improves retention and survival of transplanted mesenchymal stem cells in rat acute myocardial infarction. Cell Death Dis. (2016) 7:e2056. doi: 10.1038/cddis.2015.417

63. Liu XB, Wang JA, Ji XY, Yu SP, Wei L. Preconditioning of bone marrow mesenchymal stem cells by prolyl hydroxylase inhibition enhances cell survival and angiogenesis in vitro and after transplantation into the ischemic heart of rats. Stem Cell Res Ther. (2014) 5:111. doi: 10.1186/scrt499

64. Wang D, Shen W, Zhang F, Chen M, Chen H, Cao K. Connexin43 promotes survival of mesenchymal stem cells in ischaemic heart. Cell Biol Int. (2010) 34:415–23. doi: 10.1002/cbin.20090118

65. Qu Z, Xu H, Tian Y, Jiang J. Atorvastatin improves microenvironment to enhance the beneficial effects of BMSCs therapy in a rabbit model of acute myocardial infarction. Cell Physiol Biochem. (2013) 32:380–9. doi: 10.1159/000354445

66. Nguyen PK, Riegler J, Wu JC. Stem cell imaging: from bench to bedside. Cell Stem Cell. (2014) 14:431–44. doi: 10.1016/j.stem.2014.03.009

67. Enoki C, Otani H, Sato D, Okada T, Hattori R, Imamura H. Enhanced mesenchymal stem cell engraftment by IGF-1 improves left ventricular function in rats undergoing myocardial infarction. Int J Cardiol. (2010) 138:9–18. doi: 10.1016/j.ijcard.2009.04.012

68. Song SW, Chang W, Song BW, Song H, Lim S, Kim HJ, et al. Integrin-linked kinase is required in hypoxic mesenchymal stem cells for strengthening cell adhesion to ischemic myocardium. Stem Cells. (2009) 27:1358–65. doi: 10.1002/stem.47

69. Chun YH, Cha MJ, Song BW, Kim IK, Song H, Chang W, et al. Enhancement of MSC adhesion and therapeutic efficiency in ischemic heart using lentivirus delivery with periostin. Biomaterials. (2012) 33:1376–85. doi: 10.1016/j.biomaterials.2011.10.078

70. Khan A, Ali A, Akhter MA, Naeem N, Chotani MA, Mustafa T, et al. Preconditioning of mesenchymal stem cells with 2,4-dinitrophenol improves cardiac function in infarcted rats. Life Sci. (2016) 162:60–9. doi: 10.1016/j.lfs.2016.08.014

71. Song H, Cha MJ, Song BW, Kim IK, Chang W, Lim S, et al. Reactive oxygen species inhibit adhesion of mesenchymal stem cells implanted into ischemic myocardium via interference of focal adhesion complex. Stem Cells. (2010) 28:553–63. doi: 10.1002/stem.302

72. Bortolotti F, Ruozzi G, Falcone A, Doimo S, Dal Ferro M, Lesizza P, et al. In vivo functional selection identifies cardiostrophin-1 as a cardiac engrafment factor for mesenchymal stromal cells. Circulation. (2017) 136:1509–24. doi: 10.1161/CIRCULATIONAHA.117.029003

73. Kwon HM, Hur S, Park K, Kim C, Kim Y, Kim H, et al. Multiple paracrine factors secreted by mesenchymal stem cells contribute to angiogenesis. Vasc Pharmacol. (2014) 63:19–28. doi: 10.1016/j.vph.2014.06.004

74. Lu D, Liao Y, Zhu SH, Chen QC, Xie DM, Liao JY, et al. Bone-derived Nestin-positive mesenchymal stem cells improve cardiac function via recruiting cardiac endothelial cells after myocardial infarction. Stem Cell Res Ther. (2019) 10:127. doi: 10.1186/s13287-019-1217-x

75. Zhu W, Yuan Y, Liu C, Li L, Liu J, Chen Y, et al. Mesenchymal stem cells ameliorate hyperglycemia-induced endothelial injury through modulation of mitophagy. Cell Death Dis. (2018) 9:837. doi: 10.1038/s41419-018-0861-x

76. Xu T, Lv Z, Chen Q, Guo M, Wang X, Huang F. Vascular endothelial growth factor over-expressed mesenchymal stem cells-conditioned media ameliorate
palmitate-induced diabetic endothelial dysfunction through PI-3K/AKT/mTOR/eNOS and p38/ MAPK signaling pathway. Biomed Pharmacother. (2018) 106:491–8. doi: 10.1016/j.biopharm.2018.06.129
85. Xu L, Williameit-Romer R, Luthring-Feyerabend B. Hypoxia influences the effects of magnesium degradation products on the interactions between endothelial and mesenchymal stem cells. Acta Biomater. (2020) 101:624–36. doi: 10.1016/j.actbio.2019.10.018
86. Otto BJ, Oie E, Shahdadfar A, Karlsen T, Muller RM, Aakhus S, et al. Intramyocardial injections of human mesenchymal stem cells following acute myocardial infarction modulate scar formation and improve left ventricular function. Cell Transplant. (2012) 21:1697–709. doi: 10.3727/096389112X627462
87. Silva GV. Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model. Circulation. (2005) 111:596–604. doi: 10.1161/01.CIR.0000151812.86142.45
88. Vodyanik MA, Yu J, Zhang X, Tian S, Stewart R, Thomson JA, et al. A mesoderm-derived precursor for mesenchymal stem and endothelial cells. Cell Stem Cell. (2010) 7:718–29. doi: 10.1016/j.stem.2010.11.011
89. Wang C, Li Y, Yang M, Zou Y, Liu H, Liang Z, et al. Efficient differentiation of bone marrow mesenchymal stem cells into endothelial cells in vitro. Eur J Vasc Endovasc. (2018) 55:257–65. doi: 10.1111/evas.2017.10.012
90. Almalki SG, Agrawal DK. ERK signaling is required for VEGF-A/VEGFR2-induced differentiation of porcine adipose-derived mesenchymal stem cells into endothelial cells. Stem Cell Res Ther. (2018) 9:813. doi: 10.1186/s13287-017-0568-4
91. Murasawa S, Ashara T. Endothelial progenitor cells for vasculo genesis. Physiology. (2005) 20:36–42. doi: 10.1152/physiol0033.2004.0032
92. Zisch AH. Tissue engineering with angiogenesis of autologous endothelial progenitor cells. Curr Opin Biotechnol. (2004) 15:424–9. doi: 10.1016/j.cbpb.2004.08.005
93. Tan Y, Shu L, Xu P, Bai S. Mesenchymal stem cells attract endothelial progenitor cells via a positive feedback loop between CXCR2 and CXCR4. Stem Cells Int. (2019) 2019:4197164. doi: 10.1155/2019/4197164
94. Li Z, Yang A, Yin X, Dong S, Luo F, Dou C, et al. Mesenchymal stem cells promote endothelial progenitor cell migration, vasculogenesis, and bone repair in tissue-engineered constructs via activating CXCR2-Src-PKL/Yes2-Racl. Faseb J. (2018) 32:2197–211. doi: 10.1002/201700895R
95. Fang J, Huang X, Han X, Zheng Z, Hu C, Chen T, et al. Endothelial progenitor cells promote viability and nerve regenerative ability of mesenchymal stem cells through PDGF-BB/PDGFr-beta signaling. Aging. (2020) 12:106–21. doi: 10.18632/aging.102604
96. Rossi E, Smadja D, Goyard C, Cras A, Dizier B, Bacha N, et al. Co-injection of mesenchymal stem cells with endothelial progenitor cells accelerates muscle recovery in hind limb ischemia through an endoglin-dependent mechanism. Thromb Haemost. (2017) 117:1908–18. doi: 10.1111/1395-0303.12816
97. Yonekura H, Sakurai S, Liu X, Migita H, Wang H, Yamagishi S, et al. Hypoxia induces microRNA transfer plays a role in radiation-induced bystander effect. Oncogene. (2018) 37:2415–24. doi: 10.1038/sj.onc.123978
98. Teng X, Chen L, Chen W, Yang J, Yang Z, Shen Z. Mesenchymal stem cell–derived exosomes improve the microenvironment of infarcted myocardium contributing to angiogenesis and anti-inflammation. Cell Physiol Biochem. (2015) 37:2415–24. doi: 10.1159/000438594
99. Di Andriolo G, Provasi E, Lo CV, Brambilla A, Soncin S, Torre T, et al. Exosomes from human cardiac progenitor cells for therapeutic applications: development of a GMP-grade manufacturing method. Front Physiol. (2018) 9:1169. doi: 10.3389/fphys.2018.01169
100. Xie S, Wang J, Ding N, Hu W, Zhang X, Wang B, et al. Exosome-mediated microRNA transfer plays a role in radiation-induced bystander effect. RNA Biol. (2015) 12:1355–63. doi: 10.5966/rna.2015.1100795
101. Zhu LP, Tian T, Wang JY, He JN, Chen T, Pan M, et al. Hypoxia-elicited mesenchymal stem cell–derived exosomes facilitates cardiac repair through miR-125b-mediated prevention of cell death in myocardial infarction. Theranostics. (2018) 8:6163–77. doi: 10.7150/thno.28021
102. Steinhoff G, Nesteruk J, Wolfen M, Kuntid G, Bögermann J, David J. Cardiac function improvement and bone marrow response - outcome analysis of the randomized PERFECT phase III clinical trial of intramyocardial CD133+ application after myocardial infarction. Ebiomedicine. (2017) 22:208–24. doi: 10.1016/j.ebiom.2017.07.022
121. Wöhrlé J, Merkle N, Mailänder V, Nusser T, Schauwecker P, von Scheidt F, et al. Results of intracoronary stem cell therapy after acute myocardial infarction. Am J Cardiol. (2010) 105:804–12. doi: 10.1016/j.amjcard.2009.10.060

122. Wöhrlé J, von Scheidt F, Schauwecker P, Wiesneth M, Markovic S, Schrenzmeier H, et al. Impact of cell number and microvascular obstruction in patients with bone-marrow derived cell therapy: final results from the randomized, double-blind, placebo controlled intracoronary Stem cell therapy in patients with Acute Myocardial Infarction (SCAMI) trial. Clin Res Cardiol. (2013) 102:765–70. doi: 10.1007/s00392-013-0595-9

123. Makkar RR, Smith RR, Cheng K, Malliaras K, Thomson LE, Berman D, et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet. (2012) 379:895–904. doi: 10.1016/S0140-6736(12)60195-0

124. Malliaras K, Makkar RR, Smith RR, Cheng K, Wu E, Bonow RO, et al. Intracoronary cardiosphere-derived cells after myocardial infarction. J Am Coll Cardiol. (2014) 63:110–22. doi: 10.1016/j.jacc.2013.08.724

125. Noiseux N, Mansour S, Weisel R, Stevens L, Der Sarkissian S, Tsang K, et al. Neovascularization of MSCs in IHD: with improved perfusion and is dose dependent. Thromb Res. (2011) 128:765–8. doi: 10.1016/j.thromres.2011.11.045

126. Traverse JH. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function. JAMA. (2011) 306:2110. doi: 10.1001/jama.2011.1670

127. Bhatnagar A, Bolli R, Johnstone BH, Traverse JH, Henry TD, Pepine CJ, et al. Bone marrow cell characteristics associated with patient profile and cardiac performance outcomes in the LateTIME-Cardiovascular Cell Therapy Research Network (CCTRN) trial. Am Heart J. (2016) 179:142–50. doi: 10.1016/j.ahj.2016.06.018

128. Cogle CR, Wise E, Meacham AM, Zierold C, Traverse JH, Henry TD, et al. Detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction. Circ Res. (2014) 115:867–74. doi: 10.1161/CIRCRESAHA.114.304353

129. Traverse JH, Henry TD, Pepine CJ, Willerson JT, Zhao DXM, Ellis SG, et al. Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction. JAMA. (2012) 308:2389–90. doi: 10.1001/jama.2012.28726

130. Traverse JH, Henry TD, Pepine CJ, Willerson JT, Ellis SG. One-year follow-up of intracoronary stem cell delivery on left ventricular function following ST-elevation myocardial infarction. JAMA. (2014) 311:301. doi: 10.1001/jama.2013.282674

131. Sürder D, Manka R, Lo Cicero V, Moccetti T, Emmert MY, Klersy C, et al. PreSERVE-AMI: a randomized, double-blind, placebo controlled intracoronary Stem Cell Delivery trial of bone marrow mononuclear stem cell administration in patients following ST-elevation myocardial infarction. JAMA. (2011) 306:2110. doi: 10.1001/jama.2011.1670

132. Sürder D, Manka R, Lo Cicero V, Moccetti T, Rufibach K, Soncin S, et al. Intracoronary injection of bone marrow-derived mononuclear cells early or late after acute myocardial infarction. Circulation. (2013) 127:1968–79. doi: 10.1161/CIRCULATIONAHA.112.001303

133. Örtqvist D, Manka R, Moccetti T, Lo Cicero V, Emmett MY, Klersy C, et al. Effect of bone marrow-derived mononuclear cell treatment, early or late after acute myocardial infarction. Circ Res. (2016) 119:481–90. doi: 10.1161/CIRCRESAHA.116.308639

134. Naserni MH, Madani H, Ahmadi TS, Moskhani FM, Kazemi SD, Hosseinnejad H, et al. COMPARE CPM-RMI trial: intramyocardial transplantation of autologous bone marrow-derived CD133+ cells and MNCs during CABG in patients with recent MI: a phase II/III, multicenter, placebo-controlled, randomized, double-blind clinical trial. Cell (2018) 20:267–77.

135. Traverse JH, McKenna DH, Harvey K, Jorgensen BC, Olson RE, Bostrom N, et al. Results of a phase 1, randomized, double-blind, placebo-controlled trial of bone marrow mononuclear stem cell administration in patients following ST-elevation myocardial infarction. Am Heart J. (2010) 160:428–34. doi: 10.1016/j.ahj.2010.06.009

136. Fernández-Avilés F, Sanz-Ruiz R, Bogaert J, Casado Plascencia A, Giliberte I, Belmans A, et al. Safety and efficacy of intracoronary infusion of autologic human cardiac stem cells in patients with ST-segment elevation myocardial infarction and left ventricular dysfunction. Circ Res. (2012) 111:375–89. doi: 10.1161/CIRCRESAHA.111.2131832

137. Hu S, Liu S, Zheng Z, Yuan X, Li L, Lu M, et al. Isolated coronary artery bypass graft combined with bone marrow mononuclear cells delivered through a graft vessel for patients with previous myocardial infarction and chronic heart failure. J Am Coll Cardiol. (2011) 57:2409–15. doi: 10.1016/j.jacc.2011.01.037

138. Pättilä T, Lehtinen M, Vento A, Schildt J, Sinisalo J, Laine M, et al. Autologous bone marrow mononuclear cell transplantation in ischemic heart failure: a prospective, controlled, randomized, double-blind study of cell transplantation combined with coronary bypass. J Heart Lung Transplant. (2014) 33:567–74. doi: 10.1016/j.healun.2014.02.009

139. Lehtinen M, Pättilä T, Vento A, Kankuri E, Soojartanta-Ylinen R, Pöyhiä R, et al. Prospective, randomized, double-blind trial of bone marrow cell transplantation combined with coronary surgery — perioperative safety study. Interact Cardiovasc Thorac. Surg. (2014) 19:990–6. doi: 10.1093/icvts/ivu265

140. Huikuri HV, Kervinen K, Niemelä M, Ylitalo K, Säily M, Koistinen P, et al. Detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction. Circulation. (2014) 130:765–8. doi: 10.1161/CIRCULATIONAHA.114.017763

141. Quyyumi AA, Waller EK, Murrow J, Esteves F, Galt J, Oshinski J, et al. CD34+ cell infusion after ST elevation myocardial infarction is associated with improved perfusion and is dose dependent. Am Heart J. (2011) 161:98–105. doi: 10.1016/j.ahj.2010.09.025

142. Quyyumi AA, Vasquez A, Kereiakes DJ, Klatzolof M, Schaer GL, Abdel-Latif A, et al. PreSERVE-AMI: a randomized, double-blind, placebo-controlled...
clinical trial of intracoronary administration of autologous CD34+ cells in patients with left ventricular dysfunction post STEMI. Circ Res. (2017) 120:324–31. doi: 10.1161/CIRCRESAHA.115.308165

152. Assimus B, Honold J, Schachinger V, Britten MB, Fischer-Rasokat U, Lehmann R, et al. Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med. (2006) 355:1222–32. doi: 10.1056/NEJMoa051779

153. Hu X, Huang X, Yang Q, Wang L, Sun J, Zhan H, et al. Safety and efficacy of intracorony hypoxia-preconditioned bone marrow mononuclear cell administration for acute myocardial infarction patients: the CHINA-AMI randomized controlled trial. Int J Cardiol. (2015) 184:446–51. doi: 10.1016/j.ijca.2015.02.084

154. Guijarro D, Lebrin M, Lairez O, Bourin P, Pirio N, Pozzo J, et al. Intramyocardial transplantation of mesenchymal stem cells for chronic myocardial ischemia and impaired left ventricular function: results of the MESAMI 1 pilot trial. Int J Cardiol. (2016) 209:258–65. doi: 10.1016/j.ijca.2016.02.016

155. Hare JM, Fishman JE, Gerstenblith G, DíFeR Velazquez DL, Zambrano JP, Suncion VY, et al. Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy. JAMA. (2012) 308:2369. doi: 10.1001/jama.2012.25321

156. Hu X, Huang X, Yang Q, Wang L, Sun J, Zhan H, et al. Safety and efficacy of intracorony hypoxia-preconditioned bone marrow mononuclear cell administration for acute myocardial infarction patients: the CHINA-AMI randomized controlled trial. Int J Cardiol. (2015) 184:446–51. doi: 10.1016/j.ijca.2015.02.084

157. Van W, Lin C, Guo Y, Chen Y, Du Y, Lau WB, et al. N-Cadherin overexpression mobilizes the protective effects of mesenchymal stromal cells against ischemic heart injury through A Beta- catenin-dependent manner. Circ Res. (2020) 126:857–74. doi: 10.1161/CIRCRESAHA.119.315806

158. Zhang Z, Tian H, Yang C, Liu J, Zhang H, Wang J, et al. Mesenchymal stem cells promote the resolution of cardiac inflammation after ischemia reperfusion via enhancing efferocytosis of neutrophils. J Am Heart Assoc. (2020) 9:e14397. doi: 10.1161/JAHA.119.014397

159. Sharp TE, Schena GJ, Hobby AR, Starosta T, Berretta RM, Wallner M, et al. Cortical bone stem cell therapy preserves cardiac structure and function after myocardial infarction. Circ Res. (2017) 121:1263–78. doi: 10.1161/CIRCRESAHA.117.311174

160. Gong XH, Liu H, Wang SJ, Liang SW, Wang GG. Exosomes derived from SDF-1-overexpressing mesenchymal stem cells inhibit ischemic myocardial cell apoptosis and promote cardiac endothelial microvascular regeneration in mice with myocardial infarction. J Cell Physiol. (2019) 234:13878–93. doi: 10.1002/jcp.28070

161. Xiao C, Wang K, Xu Y, Hu H, Zhang N, Wang Y, et al. Transplanted mesenchymal stem cells reduce autophagic flux in infarcted hearts via the exosomal transfer of miR-125b. Circ Res. (2018) 123:156–78. doi: 10.1161/CIRCRESAHA.118.312758

162. Natsumeda M, Florea V, Rieger AC, Tompkins BA, Banerjee MG, Golpanian S, et al. Cortical bone stem cell therapy preserves cardiac structure and function after myocardial infarction. Circ Res. (2017) 121:1263–78. doi: 10.1161/CIRCRESAHA.117.311174

163. Babić I, Solanes N, Fernández Jiménez R, Galán Arriola C, Dantas AP, Fernández-Friera L, et al. Intracoronary administration of allogeneic adipose tissue–derived mesenchymal stem cells improves myocardial perfusion but not left ventricle function, in a translational model of acute myocardial infarction. J Am Heart Assoc. (2017) 6:e005771. doi: 10.1161/JAHA.117.005771

164. Liu X, Hu D, Zeng Z, Zhu W, Zhang N, Yu H, et al. SRT1720 promotes survival of aged human mesenchymal stem cells via FAIM: a pharmacological strategy to improve stem cell-based therapy for rat myocardial infarction. Cell Death Dis. (2017) 8:e2731. doi: 10.1038/cddis.2017.107

165. Luo L, Tang J, Nishi K, Yan C, Dinh P, Cores J, et al. Fabrication of synthetic mesenchymal stem cells for the treatment of acute myocardial infarction in mice. Circ Res. (2017) 120:1768–75. doi: 10.1161/CIRCRESAHA.116.310374

166. Liu G, Li L, Hua D, Li Y, Wu Y, Zeng L, et al. A VEGF delivery system targeting MI improves angiogenesis and cardiac function based on the tropism of MSCs and layer-by-layer self-assembly. Biomater. (2017) 127:117–31. doi: 10.1016/j.biomaterials.2017.03.001

167. Gómez-Mauricio G, Moscoso I, Martín-Cancho M, Crisóstomo V, Prat-Vidal C, Báez-Díaz C, et al. Combined administration of mesenchymal stem cells overexpressing IFG-1 and HGF enhances neovascularization but moderately improves cardiac regeneration in a porcine model. Stem Cell Res Ther. (2016) 7:94. doi: 10.1186/s13287-016-0350-z

168. de Jong R, Houtgraaf JH, Samiei S, Boersma E, Dutchs HJ. Intracoronary stem cell infusion after acute myocardial infarction: a meta-analysis and update on clinical trials. Circ Cardiovasc Interv. (2014) 7:156–67. doi: 10.1161/CIRCINTERVENTIONS.113.001009

169. Liu B, Duan C, Luo C, Ou C, Sun K, Wu Z, et al. Effectiveness and safety of selected bone marrow stem cells on left ventricular function in patients with acute myocardial infarction: A meta-analysis of randomized controlled trials. Int J Cardiol. (2014) 177:764–70. doi: 10.1016/j.ijca.2014.11.005

170. Xu J, Liu D, Zhang Y, Huang R. Effects of timing on intracoronary autologous bone marrow-derived cell transplantation in acute myocardial infarction: a meta-analysis of randomized controlled trials. Stem Cell Res Ther. (2017) 8:231. doi: 10.1186/s13287-017-0680-5

171. Li S, Tang D, Xue Z, Zhang Z, Sun X, Liu Y, et al. Biphase effect of EGr761 on simulated ischemia-induced rat BMSC survival in vitro and in vivo. Life Sci. (2011) 88:853–63. doi: 10.1016/j.lfs.2011.03.002

172. Tong Y, Xu W, Han H, Chen Y, Wang J, Qiao H, et al. Tanshinone IIA increases recruitment of bone marrow mesenchymal stem cells to infarct region via up-regulating stromal cell-derived factor-1/CXCR chemokine receptor 4 axis in a myocardial ischemia model. Phytomedicine. (2011) 18:443–50. doi: 10.1016/j.phymed.2010.10.009

173. Fosnot B, Van der Heyden J, Van den Brande G, Rapin L, Gubler-Kalb M, De Sutter A, et al. Effect of atorvastatin on circulating CD34+/CD133+/CD45− progenitor cells and indices of angiogenesis (vascular endothelial growth factor receptor-2 and -3) in atherosclerotic vascular disease and diabetes mellitus. J Intern Med. (2010) 267:385–93. doi: 10.1111/j.1365-2796.2009.01251.x

174. Yamada Y, Takeuchi S, Yoneda M, Ito S, Sano Y, Nagasaki K, et al. Atorvastatin reduces cardiac and adipose tissue inflammation in rats with metabolic syndrome. Int J Cardiol. (2017) 240:332–8. doi: 10.1016/j.ijcard.2017.04.103

175. Xu H, Yang YJ, Qian HY, Tang YD, Wang H, Zhang Q, Rosuvastatin treatment activates JAK-STAT pathway and increases efficacy of allogeneic mesenchymal stem cell transplantation in infarcted hearts. Circ J. (2011) 75:1276–85. doi: 10.1253/circj.CJ-10-1275

176. Cai A, Zhang D, Dong Y, Qiu R, Huang Y, Song Y, et al. Efficacy of Atorvastatin combined with adipose-derived mesenchymal stem cell transplantation on cardiac function in rats with acute myocardial infarction. Acta Biochim Biophys Sin. (2011) 43:857–66. doi: 10.1093/abbs/gmr087

177. Montzka K, Fuhrmann T, Muller-Ehmsen L, Wolte M, Broek GA. Growth factor and cytokine expression of human mesenchymal stromal cells is not altered in an in vitro model of tissue damage. Cytotherapy. (2010) 12:870–80. doi: 10.3109/14636532.2010.501789
182. Yao Y, Zhang F, Wang L, Zhang G, Wang Z, Chen J, et al. Lipopolysaccharide preconditioning enhances the efficacy of mesenchymal stem cells transplantation in a rat model of acute myocardial infarction. J Biomed Sci. (2009) 16:74. doi: 10.1186/1423-0127-16-74

183. Liu X, Hou J, Shi L, Chen J, Sang J, Hu S, et al. Lysophosphatidic acid protects mesenchymal stem cells against ischemia-induced apoptosis in vivo. Stem Cells Dev. (2009) 18:947–54. doi: 10.1089/scd.2008.0352

184. Jurgielewicz P, Harmien S, Wei E, Bachmann MH, Ting R, Aras O. New imaging probes to track cell fate: reporter genes in stem cell research. Cell Mol Life Sci. (2017) 74:4455–69. doi: 10.1007/s00018-017-2584-z

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Shi, Xin, Yuan, Yuan, Cong and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.